Nevertheless, the heterogeneity of the underlying studies, such as the variability in study design, time windows, tracer types, sample sizes, and disease stages, introduce uncertainty in whether early phase amyloid or tau PET could reliably replace FDG PET. Here, MAPT is linked to amyloidosis.